Companies · Biotech / Pharma

Gaingels Parallel Bio Llc

BURLINGTON · Biotech / Pharma · refined from filed group “Other

Diligence memoA one-page analyst read on Gaingels Parallel Bio Llc — recommendation, valuation, rhythm, risks.
$127K
Total raised · real
1
Rounds
Latest step-up
Top 92%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Thu Oct 21 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Gaingels Parallel Bio Llc looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech/pharma sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.58× the median modeled value of Pre-Seed Biotech / Pharma companies in 2019–2021 (15 peers) — value vs value, same stage and era.
Dormant
  • Last raise 4.7 yr ago; this sector typically re-raises about every 15 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Gaingels Parallel Bio Llc behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
4.7 yr record
Peak capital year was 2021 with $127K across 1 filings.
Market position
ahead of 9% of Biotech / Pharma peers
Capital scale is ahead of 9% of Biotech / Pharma peers; modeled value is above 19% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2021: $127K across 1 filings.
  • Largest single filing was $127K on 2021-10-21.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotech / Pharma

Gaingels Parallel Bio Llc is one of 227 Biotech / Pharma companies tracked from BURLINGTON. By capital raised it ranks in the long tail (ahead of 9% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
18
Investors (latest)
2021
Year incorporated
2021-10-21
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$1.3M$2.5M$3.8M$5.0MPre-Seed · 2021-10-21 Raised $127K (real) Modeled valuation $3.0M (est)$127K$3.0MPre-Seed2021

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$127K · 2021

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$3.0M
Base estimate est.
$69K
Conservative case
$22.6M
Upside case
$706K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech/pharma sector profile. Directional, not a quoted figure.

Not enough modeled valuation points to chart a trajectory.

Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
25%
Survival probability
10% low · 45% high
1.83×/yr
Annual markup
2.48×/yr upside case
4.7 yr
Elapsed time used
4.7 yr actual, capped for stale marks
biotech/pharma
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
Avg between rounds
Capital velocity
4.7 yr
On record since
2021
First round
1
Rounds on file
How it compares to the market

Benchmarked against 227 companies in Biotech / Pharma. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.0× of median
This company$127K
Sector median$5.6M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 0.4× of median
This company$127K
Sector median$317K
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$3.0M
Sector median$30.5M

Raised more than 9% of sector peers (real $). Modeled value above 19% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #14 of 15.

This companyCohort peer
$1.0M$10.0M$100.0M$10K$100K$1.0M$10.0MCapital raised (log)AbX Biologics, Inc. · Pre-Seed Raised $1.0M · modeled $51.2M (est)BC Green Pharmaceuticals Inc. · Pre-Seed Raised $513K · modeled $26.3M (est)Platinum Biosciences, Inc. · Pre-Seed Raised $750K · modeled $25.6M (est)Anubis Bio Corp. · Pre-Seed Raised $300K · modeled $15.3M (est)Green Star Biosciences Inc. · Pre-Seed Raised $250K · modeled $12.8M (est)Nexus Biologics, SPC · Pre-Seed Raised $146K · modeled $7.5M (est)Petri Bio Inc. · Pre-Seed Raised $255K · modeled $6.1M (est)Cinder Biological, Inc. · Pre-Seed Raised $100K · modeled $5.1M (est)Luyef Biotechnologies Inc · Pre-Seed Raised $200K · modeled $4.6M (est)Desert Mountain Biosciences, LLC · Pre-Seed Raised $200K · modeled $4.5M (est)Cranbrook Biosciences, LLC · Pre-Seed Raised $200K · modeled $4.5M (est)Gaingels Aether Bio 2021 LLC · Pre-Seed Raised $194K · modeled $4.4M (est)Gaingels Parallel Bio Llc (this company) Raised $127K · modeled $3.0M (est)Gaingels Parallel Bio Llc
CompanyStageRaised · realValue · estvs peer med.
AbX Biologics, Inc.Pre-Seed$1.0M$51.2M10.00×
BC Green Pharmaceuticals Inc.Pre-Seed$513K$26.3M5.13×
Platinum Biosciences, Inc.Pre-Seed$750K$25.6M5.00×
Anubis Bio Corp.Pre-Seed$300K$15.3M3.00×
Green Star Biosciences Inc.Pre-Seed$250K$12.8M2.50×
Nexus Biologics, SPCPre-Seed$146K$7.5M1.46×
Petri Bio Inc.Pre-Seed$255K$6.1M1.20×
Cinder Biological, Inc.Pre-Seed$100K$5.1M1.00×
Luyef Biotechnologies IncPre-Seed$200K$4.6M0.90×
Desert Mountain Biosciences, LLCPre-Seed$200K$4.5M0.88×
Cranbrook Biosciences, LLCPre-Seed$200K$4.5M0.88×
Gaingels Aether Bio 2021 LLCPre-Seed$194K$4.4M0.87×
Gaingels Parallel Bio Llc this companyPre-Seed$127K$3.0M0.58×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$127K2021-10-21$706K$3.0M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$127K2021-10-21
    • First recorded raise — entered as Pre-Seed.
    • 18 investors on this round.
Intelligence
Modeled next raise
$203K
Modeled next size est.range $132K$325K
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
David Beatty399 other2021-10
Registry & provenance

Gaingels Parallel Bio Llc is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1889738
SEC CIK
2021
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Gaingels Ochre Bio LlcBiotech / PharmaPre-Seed$122K$2.6Mnetwork1 shared operator · same sector · same stage
Gaingels 2A Biosciences LLCBiotech / PharmaPre-Seed$137K$1.3Mnetwork1 shared operator · same sector · same stage
Gaingels Glyphic Bio LLCBiotech / PharmaPre-Seed$147K$1.9Mnetwork1 shared operator · same sector · same stage
Gaingels Orange Grove Bio LLCBiotech / PharmaPre-Seed$104K$1.0Mnetwork1 shared operator · same sector · same stage
Gaingels OverT Bio LLCBiotech / PharmaPre-Seed$155K$1.5Mnetwork1 shared operator · same sector · same stage
Gaingels Trojan Bio LLCBiotech / PharmaPre-Seed$163K$1.1Mnetwork1 shared operator · same sector · same stage
Gaingels BigHat Biosciences LLCBiotech / PharmaPre-Seed$164K$2.5Mnetwork1 shared operator · same sector · same stage
Gaingels Aether Bio 2021 LLCBiotech / PharmaPre-Seed$194K$4.4Mnetwork1 shared operator · same sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Gaingels Q Bio LLCBiotech / PharmaPre-Seed$597K92%
Gaingels Transcripta Bio LLCBiotech / PharmaPre-Seed$1.7M92%
Gaingels 2A Biosciences LLCBiotech / PharmaPre-Seed$1.3M91%
Gaingels OverT Bio LLCBiotech / PharmaPre-Seed$1.5M91%
Gaingels Glyphic Bio LLCBiotech / PharmaPre-Seed$1.9M91%
Gaingels Renewal Bio LLCBiotech / PharmaPre-Seed$3.0M91%
Gaingels Oct Bio LLCBiotech / PharmaPre-Seed$10.6M90%
Gaingels Alto Pharmacy LLCBiotech / PharmaPre-Seed$9.5M90%
Frequently asked
How much funding has Gaingels Parallel Bio Llc raised?
Gaingels Parallel Bio Llc has raised approximately $127K in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Gaingels Parallel Bio Llc's estimated valuation?
Provath's modeled valuation for Gaingels Parallel Bio Llc is approximately $3.0M (modeled range $69K–$22.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Gaingels Parallel Bio Llc at?
Gaingels Parallel Bio Llc's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Thu Oct 21.
What does Gaingels Parallel Bio Llc do and where is it based?
Gaingels Parallel Bio Llc operates in the Biotech / Pharma sector, based in BURLINGTON.
Explore related

See where Gaingels Parallel Bio Llc sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Gaingels Parallel Bio Llc, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.